Patients ask me two questions about weight loss efficacy that I want to address directly before anything else. The first is: "Will this actually work for me?" The second, asked with a mix of hope and skepticism, is: "Is this as good as they say?"
The answer to both questions requires that I be precise about what the trial data shows — and equally precise about its limitations. GLP-1 medications are the most effective pharmacological weight loss tools in medical history. That's a meaningful statement, and I don't make it casually. But it doesn't mean they work equally for everyone, and it doesn't mean stopping them is consequence-free.
What Lifestyle Change Alone Actually Achieves
I want to start here, because this baseline is frequently misrepresented — both overstated by those who believe willpower and effort are sufficient, and understated by those who dismiss lifestyle intervention entirely.
The most rigorous long-term trial of lifestyle intervention for obesity is the Look AHEAD trial, which enrolled over 5,000 adults with type 2 diabetes and obesity and randomized them to intensive lifestyle intervention (weekly meetings, caloric goals, physical activity targets) versus standard care. After one year, the intensive intervention group lost an average of 8.6% of body weight. After four years, average weight loss had fallen back to 6.2% as adherence declined. After 10 years, it was 4.7%.
This is not a failure of the people enrolled. It reflects the biology of what happens when you restrict calories without modifying the hormonal environment driving hunger: the body compensates with increased ghrelin (the hunger hormone), decreased leptin (the satiety hormone), and a lowered resting metabolic rate. People aren't failing their diets. Their physiology is working against them.
The 5% weight loss figure from sustained intensive lifestyle intervention is not a dismissal of lifestyle modification — it's the true baseline against which pharmacological and surgical interventions need to be measured. And 5% weight loss is not trivial: it produces meaningful reductions in blood pressure, blood sugar, and triglycerides. But for patients with obesity-related comorbidities requiring 15–20% body weight reduction to achieve meaningful disease modification, lifestyle change alone is insufficient as a primary treatment.
What GLP-1 Medications Achieve: The Trial Numbers
Here's where the data genuinely surprised the medical community when it emerged, because the weight loss seen in the GLP-1 obesity trials exceeded anything previously achieved with medication — often approaching the results of surgical intervention.
In the STEP 1 trial (semaglutide 2.4 mg for obesity, without diabetes), participants lost a mean of 14.9% of body weight at 68 weeks, compared to 2.4% with placebo. 86.4% of semaglutide-treated participants achieved at least 5% weight loss; 69.1% achieved at least 10%; 50.5% achieved at least 15%. In the SURMOUNT-1 trial (tirzepatide 15 mg, without diabetes), mean weight loss was 20.9% at 72 weeks, compared to 3.1% with placebo. 91% of tirzepatide-treated participants achieved at least 5% weight loss; 57% achieved at least 20%. In the prediabetes sub-analysis of SURMOUNT, more than 90% of tirzepatide-treated participants had reverted to normoglycemia (non-diabetic blood sugar) by week 176 — suggesting that sufficient weight loss may arrest or reverse the trajectory toward type 2 diabetes in most patients.
The Staged Approach: What Happens When You Combine GLP-1s with Intensive Lifestyle Intervention First
One of the most striking findings in recent trials came from SURMOUNT-3, which tested a different approach: run patients through a 12-week intensive lifestyle intervention first, then start tirzepatide. The results were striking.
SURMOUNT-3 enrolled adults with obesity who had already completed a 12-week intensive lifestyle intervention (averaging about 6.9% weight loss during that phase). They were then randomized to tirzepatide versus placebo for an additional 72 weeks. Tirzepatide-treated participants went on to lose an additional 18.4% of body weight, compared to 2.5% regain with placebo — a treatment difference of 20.8 percentage points. Counting from before the lifestyle intervention began, total body weight reduction was approximately 25% from initial starting weight. This is the largest weight reduction ever observed in a medication trial and approaches Roux-en-Y gastric bypass outcomes.
The SURMOUNT-3 result changed how I counsel patients about sequencing. A period of structured lifestyle intervention before starting medication isn't necessarily wasted time — it may prime the metabolic environment, establish behavioral habits, and amplify the eventual drug response. That said, not every patient has the time, resources, or support system for a formal pre-medication lifestyle program. For many patients, starting medication and building lifestyle practices concurrently is the practical path. The key message from SURMOUNT-3 is not that you must do lifestyle first — it's that the combination can exceed either approach alone. I cover that in detail in Post 4.
What's Coming Next: Retatrutide and the Triple Agonist Era
The efficacy trajectory of this drug class has moved remarkably fast. Semaglutide pushed beyond anything previously achievable with medication. Tirzepatide, by adding GIP receptor activation, pushed further still. Retatrutide — a triple agonist targeting GIP, GLP-1, and the glucagon receptor simultaneously — appears poised to push further again, and may be available as early as late 2026 pending Phase 3 results and regulatory review.
The glucagon receptor addition is mechanistically important. Glucagon receptor activation increases energy expenditure — essentially raising the rate at which your body burns calories at rest — which is a distinct lever from appetite suppression or insulin regulation. Combining all three pathways in a single weekly injection appears to produce additive effects on both weight loss and metabolic improvement.
In a Phase 2 obesity trial of 338 participants followed for 48 weeks, retatrutide 12 mg produced a mean body weight reduction of 24.2% — a figure that overlaps with sleeve gastrectomy outcomes and exceeds anything previously seen in a medication trial. Weight loss thresholds were striking: 100% of participants lost at least 5%, 93% lost at least 10%, 83% lost at least 15%, and 25% lost 30% or more of baseline body weight. Participants were still losing weight at week 48 without reaching a plateau, suggesting the ceiling has not yet been found. In a parallel Phase 2 diabetes trial, the 12 mg dose reduced HbA1c by 2.02 percentage points versus 0.01 with placebo, and 63% of participants achieved 15% or greater weight loss — a threshold associated with potential diabetes remission. The safety profile was consistent with the broader GLP-1 class: predominantly mild-to-moderate gastrointestinal symptoms during dose escalation, no severe hypoglycemia events.
Retatrutide Phase 2 data needs to be interpreted with appropriate caution — Phase 2 trials are smaller and shorter than the Phase 3 trials we use to establish efficacy and safety for regulatory approval, and the full Phase 3 program results are not yet available. That said, the numbers are genuinely remarkable, and if they replicate at scale, retatrutide will further close the gap between pharmacological and surgical weight loss outcomes. We may be approaching a point where, for many patients, the right medication produces results indistinguishable from surgery — without the procedural risk, the irreversibility, or the lifelong nutritional monitoring surgery requires. I'm watching the Phase 3 data closely.
How GLP-1 Weight Loss Compares to Bariatric Surgery
Bariatric surgery remains the most effective long-term intervention for severe obesity. Roux-en-Y gastric bypass (RYGB) achieves an average total body weight loss of roughly 30–35% at one year and maintains 25–30% loss at five years in most studies. Sleeve gastrectomy achieves 20–25% at one year with somewhat more regain over time. These numbers are substantially better than historical medication options — but tirzepatide is closing the gap considerably.
| Outcome | Intensive Lifestyle | Tirzepatide 15 mg | Gastric Bypass |
|---|---|---|---|
| Mean % body weight lost (1–2 yr) | 4–6% | ~21% | ~30% |
| % achieving ≥15% weight loss | <5% | ~63% | ~90% |
| Type 2 diabetes remission | ~10–15% at 1 yr | ~50–60% | ~80% at 5 yr |
| Blood pressure reduction | Modest | Meaningful | Meaningful |
| Cardiovascular event reduction | Modest (from weight loss) | 20% reduction (SELECT) | Significant (observational data) |
| Requires surgery/anesthesia | No | No | Yes |
| Reversible | Yes | Yes (with weight regain) | Partially / No |
| Ongoing treatment required | Indefinite behavioral effort | Indefinite medication | Lifelong nutritional monitoring |
The surgical numbers are better — that's the honest answer. But surgery carries perioperative risks (roughly 0.1–0.3% mortality for RYGB at high-volume centers), requires lifelong nutritional supplementation and monitoring, and is irreversible. For patients with a BMI of 35–45 without severe comorbidities, many physicians and patients will reasonably prefer a medication-based approach that achieves 70–80% of the surgical benefit without the procedural risk.
The calculus shifts for patients with a BMI above 50, those with severe obesity-related comorbidities requiring maximal weight loss, or those who have tried GLP-1 medications without adequate response. For those patients, surgical referral remains appropriate.
The Critical Question: What Happens When You Stop?
This is where I must be absolutely clear with patients, because this is the most important piece of information in this entire post, and it's often omitted from the more optimistic coverage of these medications.
If you stop taking a GLP-1 medication, you will regain most of the weight you lost. This is not a failure of the drug — it's precisely what you'd expect from the mechanism. The medication was suppressing hunger signals and slowing gastric emptying. When it's gone, those signals return. If the underlying metabolic drivers of obesity haven't changed, the weight comes back.
The SURMOUNT-4 trial made this dramatically clear. Participants first completed 36 weeks of open-label tirzepatide, achieving an average of approximately 21% body weight loss. They were then randomized to continue tirzepatide or switch to placebo for another 52 weeks. Those who continued tirzepatide lost an additional 5.5%. Those switched to placebo regained approximately 14% of body weight — recovering most of what they had lost — with parallel reversal of improvements in blood pressure, waist circumference, triglycerides, and HbA1c. A meta-analysis of 8 randomized trials found participants regained an average of 9.69 kg after discontinuation of semaglutide or tirzepatide.
Obesity is a chronic disease. The framing that matters here is the same one we use for blood pressure or cholesterol: we don't expect people to take lisinopril for five years and then stop because their blood pressure is now controlled. The treatment is controlling the disease. Stop the treatment, and the disease returns. I counsel my patients from the very first appointment that GLP-1 therapy, if it works for them, is likely to be a long-term commitment — not a short course. That changes the financial, lifestyle, and medical planning conversation considerably. Patients who understand this going in make better decisions and have better outcomes.
That raises the obvious follow-up question: if this is indefinite treatment, what does sustainable long-term management actually look like? What does the evidence say about maintenance dosing, who responds best, and how sex affects your likely outcome? That's the subject of Post 4.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
- Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT). N Engl J Med. 2025.
- Wadden TA, et al. Tirzepatide After Intensive Lifestyle Intervention (SURMOUNT-3). Nature Medicine. 2023.
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
- Berg S, et al. Discontinuing GLP-1 Receptor Agonists and Body Habitus: A Systematic Review and Meta-Analysis. Obesity Reviews. 2025.
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Phase 2 Trial. Lancet. 2023.
- Gonzalez-Rellan MJ, Drucker DJ. New Molecules and Indications for GLP-1 Medicines. JAMA. 2025.
- Yanovski SZ, Yanovski JA. Approach to Obesity Treatment in Primary Care: A Review. JAMA Intern Med. 2024.
- American Diabetes Association. Standards of Care in Diabetes — 2026. Diabetes Care. 2026.